ICML 2019: The rise of CAR T-cell therapy: where are we in the US and Europe?

L:

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Loretta Nastoupil, MD Anderson Cancer Center, Houston, US and Peter Borchmann, University of Cologne, Cologne, DE, who discuss the use of CAR T-cell therapy in the US and in European countries.

Peter Borchmann mentioned how only 60 patients have been treated in France, with even less in Germany, and as such Europe is still far behind the US in its use of CAR T-cell therapy. Loretta Nastoupil talks about how the role of allogeneic transplantation has fallen behind that of CAR T, but is still needed as only around 40% of patients are successfully treated with CAR T-cell therapy. They both agree that treatments have been rapidly evolving, with effective therapies currently available that did not exist for patients five years ago.